Achillion Provides Update on Clinical HCV Development Programs, Announces New Phase 1b Clincal Trial

Achillion Pharmaceuticals

today provided an update on the sovaprevir and ACH-3102 clinical development programs and announced new Phase 1b clinical trial results on ACH-2684.  Sovaprevir and ACH-3102 Development Update Achillion announced today the completion of a drug-drug interaction (DDI) study evaluating the combination of sovaprevir and ACH-3102. The study, conducted in 24 healthy volunteers, concluded that there was no interaction between the two investigational compounds and that both sovaprevir and ACH-3102 were safe and well-tolerated by study participants with no significant adverse events reported. "With the completion of this DDI study, we now plan to submit to the FDA a Phase 2 protocol that will evaluate an all-oral, interferon-free regimen containing sovaprevir and ACH-3102 for 12 weeks and, pending discussions with the regulatory agency, we intend to initiate this combination study with the goal of reporting rapid virologic response, or RVR, in the first half of 2013," stated Michael D. Kishbauch, President and Chief Executive Officer of